This year’s chairpersons at the conference on compounds are:

  • Vulpetti Dr. Anna Vulpetti
    Research Investigator
    Novartis International AG
  • ten-Holte Dr. Peter ten Holte
    Associate Head of External, Collaborations & Outsourcing Services
    Janssen Pharmaceutica NV

  • Meet these experts amongst others:

    Czechtizky Dr. Werngard Czechtizky
    Group leader
    Sanofi-Aventis, Deutschland GmbH
  • Lessel Dr. Uta Lessel
    Principal Scientist, Department of Lead
    Generation and Optimization Support
    Boehringer Ingelheim Pharma GmbH & Co. KG

The conference on compound libraries gives you a great insight into the latest developments and best practice solutions

In order to shorten the process, reduce costs and achieve an optimal outcome on the way to promising candidates, one must choose a smart library design from the very beginning.
Diese Konferenz richtet sich an Fachkräfte in der pharmazeutischen Forschung

Learn about the newest and most effective library designs and screening methods in order to better manage your collections

Generating or acquiring new compound library collections, successfully integrating them into an existing library and running the necessary screenings are also important aspects of the process. However, the challenges are not only technological but also organizational in nature. Today more than ever achieving hit-to-lead optimization must be interlinked with innovative outsourcing, acquisition and cooperation models.

Read the full agenda here and see all expert speakers!


The 7th annual conference on compounds will provide great insights into the following topics:

  • Listen to lessons-learnt from Pfizer’s file enrichment and library design strategies in order to better understand the challenges ahead
  • Learn how to rapidly detect starting points for med-chem optimization by employing rational design of focused and fragment libraries
  • Improve hit identification by finding out more on latest technologies such as SPR and Isothermal Titration Calorimetry and 19F – NMR
  • Enhance your screening collection strategies by learning more on the process of acquiring and integrating lead-like compounds
  • Learn about blind screening by understanding better the evolution of compound acquisition and the “no cure – no pay” principle

Do not miss this opportunity to hear the latest trends and strategies from invited pharma companies such as:

  • Pfizer Limited, UK
  • Sanofi Aventis GmbH, Germany
  • Novartis International AG, Switzerland
  • Janssen Pharmaceutica NV, Belgium
  • Boehringer Ingelheim Pharma GmbH & Co. KG, Germany
  • Centre National de la Recherche Scientifique, France
  • AnalytiCon Discovery GmbH, Germany
  • UCB S.A. Belgium
  • The Leibniz-Institut für Molekulare Pharmakologie, Germany
  • Marine Biodiscovery Discovery Centre, University of Aberdeen, Scotland, UK
  • F. Hoffmann-La Roche Ltd., Switzerland
  • Grünenthal GmbH, Germany
  • GlaxoSmithKline, UK

Our interactive workshop day provides you with the latest developments in compounds

Workshop A: Ten years of building and screening the Pfizer File Enrichment Collection

Workshop D: New business models for compound library acquisition

Download the full agenda here!

We have arranged this conference for the following departments in the industries of international pharmaceuticals and biotechnolgy as well as their leading experts:

  • Compound Management
  • Compound Library/Compound Library Design
  • Medicinal Chemistry
  • Computational Chemistry
  • Combinatorial Chemistry
  • Compound Acquisition
  • Compound Profiling
  • Molecular Modelling
  • Lead Discovery
  • Lead Generation
  • Library Informatics
  • Screening
  • Discovery Research
  • Chemoinformatics
  • Analytical Chemistry

Testimonials

High content symposium. Lots of possibilites for networking. Good variety in topicsPetra Blom, Director, Asclepia MedChem Solutions
Excellent conference, not too many people so it is favourable for networking.Rimma Sushko, Manager Marketing & Sales, Life Chemicals Inc.
To the best of my knowledge this would be the first time anyone from Pfizer has spoken about the impact the file enrichment initiative has had on hit, lead and candidate discovery.Dr. Mark Gardner, Associate Research Fellow, Pfizer UK
Sponsor Media Partners
animation_sponcer Animated_Media

[ Register Now ]